BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes medicines for rare genetic diseases, with a focus on genetically defined conditions including skeletal disorders, enzyme deficiencies, and metabolic diseases. The company generates revenue through eight approved therapies across two business units—Skeletal Conditions and Enzyme Therapies—which are marketed directly in the U.S., Europe, and select other markets, while distributed through partnerships and specialty pharmacies; it also derives revenue from a collaboration with Sanofi on an enzyme replacement therapy. BioMarin's business model combines revenue from established commercial products with growth from its clinical pipeline of candidates targeting unmet genetic conditions, while also pursuing strategic acquisitions to expand its portfolio, and it manufactures certain active pharmaceutical ingredients in-house at facilities in California and Ireland while contracting most drug product manufacturing externally.